# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

### FORM 8-K

#### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): March 9, 2015

## MEDNAX, INC.

, , , , , , , , , , , , , , , , , , ,			
(Exact Name of Registrant as Specified in Its Charter)			
	Florida	001-12111	26-3667538
	(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
	incorporation)	Number)	
1301 Concord Terrace			
Sunrise, Florida 33323  (Address of principal executive office) (zip code)			
Registrant's telephone number, including area code <u>(954) 384-0175</u>			
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:			
	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)		
	Soliciting material pursuant to Rule 14a-12 under	the Exchange Act (17 CFR 240.14a-12)	
	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))		
	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))		

### Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 9, 2015, Roger K. Freeman, M.D., a director of MEDNAX, Inc. (the "Company"), advised the Company that he intends to retire from the Board of Directors of the Company (the "Board"), at the end of his current term, and will therefore not stand for re-election to the Board at the Company's 2015 annual meeting of shareholders, currently scheduled to be held on May 7, 2015.

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 13, 2015

MEDNAX, INC.

By: /s/ Vivian Lopez-Blanco

Vivian Lopez-Blanco Chief Financial Officer